Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis

Abstract The approval of bedaquiline has placed energy metabolism in the limelight as an attractive target space for tuberculosis antibiotic development. While bedaquiline inhibits the mycobacterial F1F0 ATP synthase, small molecules targeting other components of the oxidative phosphorylation pathwa...

Full description

Bibliographic Details
Main Authors: Bei Shi Lee, Kiel Hards, Curtis A Engelhart, Erik J Hasenoehrl, Nitin P Kalia, Jared S Mackenzie, Ekaterina Sviriaeva, Shi Min Sherilyn Chong, Malathy Sony S Manimekalai, Vanessa H Koh, John Chan, Jiayong Xu, Sylvie Alonso, Marvin J Miller, Adrie J C Steyn, Gerhard Grüber, Dirk Schnappinger, Michael Berney, Gregory M Cook, Garrett C Moraski, Kevin Pethe
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:EMBO Molecular Medicine
Subjects:
Online Access:https://doi.org/10.15252/emmm.202013207